 | Expand the Helsinn Groups product pipeline by acquiring new molecules in existing therapeutic focus classes and in new niche areas with priority in oncology supportive care, pain and inflammation, gastrointestinal, orphan drugs and late stage products |
| Identify new forms of J-V or strategic and financial co-operation in R&D/Licensing |
| Company development in the USA: Helsinn Therapeutics (US) Inc. |
| Become a focused leading company in Oncology Supportive Care |
| Increase market penetration through our established network of distributors worldwide (USA, EU, Japan, ROW) |
| Increase new third party chemical business by offering new potential partners integrated services of development and manufacturing in API, HPAI and new Oral Solid Dosage plant in Ireland |
